Abstract
N/A
Highlights
The objective of this analysis was to assess percentage improvement in Psoriasis Area and Severity Index (PASI) as well as absolute PASI response through 5 years of continuous GUS treatment
In VOYAGE 1, 837 patients were randomized in a 2:1:2 ratio to receive:
O GUS Group: Includes patients randomized to GUS at baseline and those randomized to PBO at baseline who crossed (n=329)
Summary
In VOYAGE 1, 837 patients were randomized in a 2:1:2 ratio to receive:. In addition to patients randomized to GUS, PBO, and ADA at baseline, treatment groups analyzed:. In addition to patients randomized to GUS, PBO, and ADA at baseline, treatment groups analyzed:. O GUS Group: Includes patients randomized to GUS at baseline and those randomized to PBO at baseline who crossed (n=329). O ADA crossover to GUS (ADA→GUS) Group: Includes patients randomized to ADA at baseline who crossed over to o ADA 80 mg SC at Week 0, 40 mg at Week 1, 40 mg every 2 weeks through Week 47, followed by GUS 100 mg at Week 52, q8w (n=334). CONCLUSIONS Continuous treatment with GUS provided robust and durable skin responses based on percentage improvement in PASI as well as absolute PASI through 5 years. Disease characteristics, and prior psoriasis treatments were generally similar across treatment groups (Table 1)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
